Podcast appearances and mentions of Bryan A Cotton

Join us after hours at Dr. Bryan A. Cotton's pop-up bourbon bar at the AAST 2022 Meeting in Chicago. In this FANTASTIC & FUN episode, we talk amongst friends about cutting edge research at this year's meeting. To no one's surprise, coagulopathy, damage control resuscitation, whole blood, and factor replacement therapy just happen to be but a few of the topics discussed on Rounds.Time Stamps:00:12 AAST 2022 - Intro00:42 Sex diamoprhisms in coagulation01:52 Hemostatic profiles of female donors02:48 Pediatric whole blood (WB) is safe03:10 WB for TBI03:31 Leukoreduction is unnecessary05:30 TXA, TEG  and trauma06:44 STAAMP trial07:21 TXA: go early, big or go home07:52 Calcium...early!09:33 Canadian perspective on TXA and TEG – Neil Perry from London, ON11:25 Nori Bradley from Edmonton, AB13:53 Jordan Weinberg, not Canadian – Phoenix, AZ16:12 Issues with WB – COMBAT vs PAMPer17:31 Cold stored platelets18:22 Rapid transfusers and whole blood: Only the strong survive!!19:42 How are we doing with our resuscitation? 1:1:1 is just the beginning, not the end!21:44 Timing is everything!23:38 Plasma first resuscitation: “…God damn good!” -BAC24:37 Dr. Joshua B. Brown - Pittsburgh, PA25:31 More Canadian perspectives with Perry and Bradley29:48 Less is best!31:27 Prothrombin complex concentrate: Yay or nay?32:18 More on the endotheliopathy of trauma33:38 Just messing around and having a blast34:22 What was the best bourbon tonight?References:CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14. PMID: 20554319.Gruen DS, Guyette FX, Brown JB, Okonkwo DO, Puccio AM, Campwala IK, Tessmer MT, Daley BJ, Miller RS, Harbrecht BG, Claridge JA, Phelan HA, Neal MD, Zuckerbraun BS, Yazer MH, Billiar TR, Sperry JL. Association of Prehospital Plasma With Survival in Patients With Traumatic Brain Injury: A Secondary Analysis of the PAMPer Cluster Randomized Clinical Trial. JAMA Netw Open. 2020 Oct 1;3(10):e2016869. doi: 10.1001/jamanetworkopen.2020.16869. PMID: 33057642; PMCID: PMC7563075.Guyette FX, Brown JB, Zenati MS, Early-Young BJ, Adams PW, Eastridge BJ, Nirula R, Vercruysse GA, O'Keeffe T, Joseph B, Alarcon LH, Callaway CW, Zuckerbraun BS, Neal MD, Forsythe RM, Rosengart MR, Billiar TR, Yealy DM, Peitzman AB, Sperry JL; STAAMP Study Group. Tranexamic Acid During Prehospital Transport in Patients at Risk for Hemorrhage After Injury: A Double-blind, Placebo-Controlled, Randomized Clinical Trial. JAMA Surg. 2020 Oct 5;156(1):11–20. doi: 10.1001/jamasurg.2020.4350. Epub ahead of print. Erratum in: JAMA Surg. 2021 Jan 1;156(1):105. PMID: 33016996; PMCID: PMC7536625.Moore HB, Moore EE, Chapman MP, McVaney K, Bryskiewicz G, Blechar R, Chin T, Burlew CC, Pieracci F, West FB, Fleming CD, Ghasabyan A, Chandler J, Silliman CC, Banerjee A, Sauaia A. Plasma-first resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a randomised trial. Lancet. 2018 Jul 28;392(10144):283-291. doi: 10.1016/S0140-6736(18)31553-8. Epub 2018 Jul 20. PMID: 30032977; PMCID: PMC6284829.Pusateri AE, Moore EE, Moore HB, Le TD, Guyette FX, Chapman MP, Sauaia A, Ghasabyan A, Chandler J, McVaney K, Brown JB, Daley BJ, MSupport the show

In this, our 50th episode, we are in Austin, TX, for the Annual EAST Scientific Meeting where we are joined by Dr. Bryan A. Cotton who shares his expertise and knowledge regarding the use of whole blood (WB) in trauma patients. From the use of whole blood in prior military conflicts to the design and successful implementation of one of the only prospective randomized controlled trials of modified whole blood use in trauma patients, Dr. Cotton provides an incredible overview of the potential benefits of whole blood or as he refers to it - "the dying blood product". Also covered in expert fashion are the role of other hemostatic products and strategies including tranexamic acid, fibrinogen concentrates, and a plasma first resuscitation strategy. Time Stamps:01:16  The rationale for whole blood & a 1:1:1 transfusion strategy04:24  Military experience with WB: What's old is new again!05:44  Modified WB vs. Component Therapy RCT06:02  Leukoreduction of WB07:00  Type-specific WB09:38  Platelet function in WB vs. aphaeresis platelets11:58  Warm fresh WB vs. cold stored12:55  The whole is greater than the sum of its parts15:02  What do we mean by low-titer WB?19:14  O+ vs. O- WB & the potential for alloimmunization24:39  Transfusion reactions & safety of WB in trauma patients25:40  Prehospital WB for the win27:32  LITES Network28:27  Hemorrhage control, 1:1:1, viscoelastic assays, cryoprecipitate & fibrinogen               concentrate32:00  BAC's thoughts on tranexamic acid (TXA)34:47  BAC's thoughts on hypertonic saline (HTS) for COVID-1938:51  Final thoughts & future directionsRecommended Readings:Cotton BA, Podbielski J, Camp E, Welch T, del Junco D, Bai Y, Hobbs R, Scroggins J, Hartwell B, Kozar RA, Wade CE, Holcomb JB; Early Whole Blood Investigators. A randomized controlled pilot trial of modified whole blood versus component therapy in severely injured patients requiring large volume transfusions. Ann Surg. 2013 Oct;258(4):527-32; discussion 532-3.Williams J, Merutka N, Meyer D, Bai Y, Prater S, Cabrera R, Holcomb JB, Wade CE, Love JD, Cotton BA. Safety profile and impact of low-titer group O whole blood for emergency use in trauma. J Trauma Acute Care Surg. 2020 Jan;88(1):87-93. McGinity AC, Zhu CS, Greebon L, Xenakis E, Waltman E, Epley E, Cobb D, Jonas R, Nicholson SE, Eastridge BJ, Stewart RM, Jenkins DH. Prehospital low-titer cold-stored whole blood: Philosophy for ubiquitous utilization of O-positive product for emergency use in hemorrhage due to injury. J Trauma Acute Care Surg. 2018 Jun;84(6S Suppl 1):S115-S119. Sperry JL, Guyette FX, Brown JB, Yazer MH, Triulzi DJ, Early-Young BJ, Adams PW, Daley BJ, Miller RS, Harbrecht BG, Claridge JA, Phelan HA, Witham WR, Putnam AT, Duane TM, Alarcon LH, Callaway CW, Zuckerbraun BS, Neal MD, Rosengart MR, Forsythe RM, Billiar TR, Yealy DM, Peitzman AB, Zenati MS; PAMPer Study Group. Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock. N Engl J Med. 2018 Jul 26;379(4):315-326. doi: 10.1056/NEJMoa1802345. PMID: 30044935.Yazer MH, Jackson B, Sperry JL, Alarcon L, Triulzi DJ, Murdock AD. Initial safety and feasibility of cold-stored uncrossmatched whole blood transfusion in civilian trauma patients. J Trauma Acute Care Surg. 2016 Jul;81(1):21-6. doi: 10.1097/TA.0000000000001100. PMID: 27120323.Websites:LITES Networkhttps://www.litesnetwork.orgSouthwest Texas Regional Advisory Councilhttps://www.strac.org/bloodSupport the show (https://www.patreon.com/traumaicurounds)

Bryan A. Cotton, MD, MPH, discusses damage control resuscitation with new iCritical Care Podcast editor Jeffrey Guy, MD, MSc, MMHC.

Bryan A. Cotton, MD, MPH, discusses damage control resuscitation with new iCritical Care Podcast editor Jeffrey Guy, MD, MSc, MMHC.